An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects 1 and 30 Years of Age with Relapsed/Refractory Precursor B-cell or T-cell Acute Lympholastic Leukemia or Lymphoblastic Lymphoma
This Study is
No Longer Enrolling
Details
Age
Child to Adult
Type of Study
Treatment
Locations
Childrens Hospital Colorado
Study ID
Protocol Number: 18-0867
More information available at ClinicalTrials.gov: NCT03384654
Categories
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers